Schematic of a genetically engineered cell membrane-coated nanoparticle designed to deliver dexamethasone to inflamed lungs.
Credit: Zhang Lab
Nanoengineers at the University of California San Diego have developed immune cell-mimicking nanoparticles that target inflammation in the lungs and deliver drugs directly where they’re needed.
As a proof of concept, the researchers filled the nanoparticles with the drug dexamethasone and administered them to mice with inflamed lung tissue. Inflammation was completely treated in mice given the nanoparticles, at a drug concentration where standard delivery methods did not have any efficacy.
The researchers reported their findings in Science Advances on June 16.
What’s special about these nanoparticles is that they are coated in a cell membrane that’s been genetically engineered to look for and bind to inflamed lung cells. They are the latest in the line of so-called cell membrane-coated nanoparticles that have been developed by the lab of UC San Diego nanoengineering professor Liangfang Zhang. His lab has previously used cell membrane-coated nanoparticles to absorb toxins produced by MRSA; treat sepsis; and train the immune system to fight cancer. But while these previous cell membranes were naturally derived from the body’s cells, the cell membranes used to coat this dexamethasone-filled nanoparticle were not.
“In this paper, we used a genetic engineering approach to edit the surface proteins on the cells before we collected the membranes. This significantly advanced our technology by allowing us to precisely overexpress certain functional proteins on the membranes or knockout some undesirable proteins,” said Zhang, who is a senior author of the paper.
Joon Ho Park, a graduate student in Zhang’s lab and first author of the paper, said the researchers noticed that when endothelial cells become inflamed, they overexpress a protein called VCAM1, whose purpose is to attract immune cells to the site of inflammation. In response, the immune cells express a protein called VLA4, which seeks out and binds to VCAM1.
“We engineered cell membranes to express the full version of VLA4 all the time,” said Park. “These membranes constantly overexpress VLA4 in order to seek out VCAM1 and the site of inflammation. These engineered cell membranes allow the nanoparticle to find the inflamed sites, and then release the drug that’s inside the nanoparticle to treat the specific area of inflammation.”
While the nanoparticle won’t directly enhance the efficacy of the drug—dexamethasone in this case—concentrating it at the site of interest may mean a lower dosage is required. This study showed that the dexamethasone accumulated at the site of interest at higher levels, and faster, than standard drug delivery approaches.
“We’re delivering the exact same drug used in the clinic, but the difference is we’re concentrating the drugs to the point of interest,” said Park. “By having these nanoparticles target the inflammation site, it means a larger portion of the medicine will wind up where it’s needed, and not be cleared out by the body before it can accumulate and be effective.”
The researchers note that this genetically engineered cell membrane approach is a platform technology that in theory can be used to target not only inflammation in other areas of the body— VCAM1 is a universal signal of inflammation—but much broader use cases as well.
“This is a versatile platform, not just for lung inflammation but any type of inflammation that upregulates VCAM1,” said Park. “This technology can be generalized; this engineered cell membrane-coated nanoparticle doesn’t have to overexpress VLA4, it could be swapped out to another protein that can target other areas of the body or accomplish other goals.”
To engineer the cell membranes to overexpress the VLA4 protein, Park and the team start with packaging VLA4 genes into a viral vector. They then insert this reprogrammed viral vector into lab-grown host cells derived from mice. The cells incorporate the genes that the viral vector is carrying into their own genome and as a result, produce membranes that constantly overexpress VLA4.
The researchers’ next step is to study the process using human cell membranes, instead of mice cell membranes, that are engineered to express the human version of VLA4. There are still many steps needed before the technology could be tested in human clinical trials, but the researchers say that these early results from the platform technology are encouraging.
“By leveraging the established gene editing techniques, this study advances the cell membrane-coated nanoparticles to a new level and opens up new opportunities for targeted drug delivery and other medical applications”, concluded by Zhang.
Original Article: Genetically Engineered Nanoparticle Delivers Dexamethasone Directly to Inflamed Lungs
More from: University of California San Diego
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug delivery via nanoparticles
- Nanotechnology in Therapeutics
Nanomedicine. 2012;7(8):1253-1271. Although passive targeting approaches form the basis of clinical therapy, they suffer from several limitations. Ubiquitously targeting cells within a tumor is ...
- How Gene Editing Therapies Could Go Beyond Rare Diseases
In the wake of the first CRISPR medicine, scientists are working to develop gene editing therapies for diseases like cystic fibrosis, ALS and cardiovascular disease.
- Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery ...
- Nanoparticle researchers develop microfluidic platform for better delivery of gene therapy for lung disease
Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.
- Efficient intranasal delivery of agomelatine via micellar encapsulation
Announcing a new publication for Acta Materia Medica journal. Agomelatine (AGO) is an antidepressant with limited clinical application due to its low bioavailability caused by poor water solubility, ...
Go deeper with Google Headlines on:
Drug delivery via nanoparticles
[google_news title=”” keyword=”drug delivery via nanoparticles” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Genetically engineered cell membrane
- Hope for Back Pain: Gene Therapy Restores Disc Health in Mice
Is back pain a constant struggle? Discover how gene therapy alleviates pain and repairs damaged discs in mice, offering hope for future treatments.
- Gene Delivery Vehicle Shows Promise for Human Gene Therapy
Gene therapy could potentially treat a range of severe genetic brain disorders ... Then they test the most promising candidates in cells and mice that have been modified to express the protein. As ...
- Nanocarriers loaded with DNA relieve back pain, repairs damaged disk in mice
Disk-related back pain may one day meet its therapeutic match: Gene therapy delivered by naturally derived nanocarriers that, a new study shows, repairs damaged disks in the spine and lowers pain ...
- An electrifying discovery may help doctors deliver more effective gene therapies
In an effort to improve delivery of costly medical treatments, a team of researchers in electrical engineering ... or introducing new genetic material into a patient's cells, doctors may be ...
- Marsupial genomes reveal how a skin membrane for gliding evolved
After forcing prolonged expression of Emx2 in the lateral skin of genetically engineered mice, the authors observed an increase in cell proliferation and the density of cells in the tissue ...
Go deeper with Google Headlines on:
Genetically engineered cell membrane
[google_news title=”” keyword=”genetically engineered cell membrane” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]